Results 131 to 140 of about 21,372 (208)

Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study

Therapeutic Advances in Hematology
Background: The response rate of traditional first-line induction chemotherapy (IC) for newly diagnosed acute myeloid leukemia needs to be improved, but it is not clear whether adding venetoclax or hypomethylating agents (HMAs) to IC will improve the ...
Fangfei Xu, Kuangguo Zhou, Duanhao Gong, Wei Huang   +3 more
doaj   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Durable Remission in Blast‐Phase Chronic Myeloid Leukemia Presenting as Early T‐Cell Precursor Acute Lymphoblastic Leukemia

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Introduction The presentation of chronic myeloid leukemia (CML) in the blast phase as early T‐cell precursor acute lymphoblastic leukemia (ETP‐ALL) is very rare. As previously reported, in contrast to B‐ALL, the prognosis is poor. Case Presentation We encountered a patient with blast phase CML presenting as ETP‐ALL.
Takafumi Tsushima, Yukiko Konishi, Natsumi Yoda, Koichiro Wada, Kento Okamoto, Kosuke Matsuo, Shuntaro Isogai, Sonoko Shimoji, Yoshikazu Utsu, Shin‐Ichi Masuda, Nobuyuki Aotsuka   +10 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia

Background: Acute myeloid leukemia (AML) is a common and aggressive form of leukemia, yet current treatment strategies remain insufficient. Venetoclax, a BH3-mimetic approved for AML treatment, induces Bcl-2-dependent apoptosis, though its therapeutic ...
Kenta Yamasaki, Tatsushi Yoshida, Renshi Kawakatsu, Kenjiro Tadagaki, Yasumichi Kuwahara   +4 more
core   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Venetoclax in the Therapeutic Strategy for BPDCN Management

Background Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials.
Fredon, Maxime, Adotévi, Olivier, Francine Garnache‐Ottou, Francis Bonnefoy, Marie Kroemer, Romain Boidot, Fanny Angelot‐Delettre, Imane Belakri, Boichut, Morgane, Bonnefoy, Francis, Angelot-Delettre, Fanny, Evan Seffar, Morgane Boichut, Saas, Philippe, Maxime Fredon, Sophie Bonnot‐Perrin, Biichle, Sabeha, Kroemer, Marie, Elodie Bôle‐Richard, Bonnot-Perrin, Sophie, Garnache-Ottou, Francine, Florian Renosi, Philippe Saas, Margaux Poussard, Belakri, Imane, Boidot, Romain, Seffar, Evan, Olivier Adotévi, Sabeha Biichle, Poussard, Margaux, Renosi, Florian, Bôle-Richard, Elodie   +31 more
core   +1 more source

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment

European Journal of Haematology, Volume 117, Issue 4, Page 787-798, October 2026.
ABSTRACT Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low‐dose cytarabine, hydroxyurea, or supportive care, with
Antonella Bruzzese, Enrica Antonia Martino, Santino Caserta, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

Optimal Hypoxia Mimetic Small Molecules for Enhancing Angiogenic Properties of Stem Cells From Human Exfoliated Deciduous Teeth

International Endodontic Journal, Volume 59, Issue 10, Page 2122-2142, October 2026.
ABSTRACT Aim Hypoxic preconditioning of cells holds promise for regenerative therapies, yet identifying effective and safe methods for clinical application remains challenging. We aimed to determine optimal hypoxia‐mimetic small molecules (SMs) that stabilize hypoxia‐inducible factor‐1α (HIF‐1α) and their dosages for hypoxic preconditioning in stem ...
Hong Wang, Jiawei Liu, Xintao Yang, Mohamad Koohi‐Moghadam, Shuting Gao, Yuanyuan Han, Dineshi Sewvandi Thalakiriyawa, James Kit Hon Tsoi, Yanqi Yang, Waruna Lakmal Dissanayaka   +9 more
wiley   +1 more source

Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia. [PDF]

Blood Adv
McKeague S, Lew TE, Lowe A, Lau L, Thompson PA, Whitechurch A, Carney D, Wolf M, Reynolds G, Blombery P, Seymour JF, Roberts AW, Anderson MA.   +12 more
europepmc   +1 more source

Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance. [PDF]

Genes (Basel)
Rojas A, Jethi S, Budak-Alpdogan T, Pandey MK.   +3 more
europepmc   +1 more source